SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing significant momentum and heavy short-covering as investors closely monitor the REGAL Phase 3 trial for the 80th clinical event. The community is actively discussing the potential for a curative AML treatment, the implications of successful immunotherapy data, and increasing speculation regarding strategic partnerships or high-stakes buyout interest.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is in the spotlight as investors weigh the company's aggressive pivot toward AI infrastructure against the financial pressure of mounting capital expenditures, a strategy that has sparked intense debate over the firm's long-term value. Market participants are closely watching the stock ahead of earnings, particularly as community sentiment remains polarized between those betting on an AI-driven turnaround and critics wary of the company's historical performance and the risks associated with the Chinese equity market.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors react to a significant new partnership with Google that includes a major custom-chip agreement and a multibillion-dollar warrant deal. While the community is debating the long-term potential of this expansion against concerns about share dilution and the stock's recent volatility, many are closely monitoring its performance ahead of the upcoming earnings report.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await clarity on the FDA's regulatory decision, with the community split between those anticipating a PDUFA extension for an amended BLA and those fearing a complete response letter. Shareholders are actively debating the impact of a recent activist letter from Kaos Capital and the potential for a short squeeze if regulatory news provides a path forward.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors weigh strong Briumvi sales growth and raised full-year guidance against an earnings miss caused by strategic manufacturing investments, while the community remains hyper-focused on buyout speculation and the upcoming subcutaneous formulation data.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is surging alongside the broader crypto market, with community members actively discussing a potential bull cycle driven by institutional ETF inflows and mounting anticipation for regulatory developments. Traders are closely watching key technical resistance levels as sentiment shifts toward a more bullish outlook.

TOSHI

Toshi is trending as investors aggressively discuss a potential short squeeze and await catalysts like upcoming exchange listings and broader market recovery. The community remains highly focused on accumulating tokens, viewing current levels as a key accumulation phase before a anticipated breakout.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Community sentiment remains polarized, with some investors highlighting SQD's role in decentralized blockchain data infrastructure as a high-potential utility asset, while critics dismiss it as a speculative pump-and-dump scheme. Discussions are heavily focused on the project's technical integration with Rezolve AI, upcoming tokenomics updates, and intense debate over its long-term viability versus short-term market volatility.

Ethena

The Ethena community is actively discussing structural upside and massive NAV discounts, with significant conversation focused on the concentration of ENA tokens backing each share of the linked public stock. Traders are closely monitoring the token's price action as a gauge for potential rallies, while speculating on how institutional relationships and treasury accumulation strategies might drive long-term value.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are oscillating following a volatile week driven by intense speculative trading and a squeeze sparked by positive Phase 3 trial data for its personalized cancer vaccine. The community remains deeply divided, with bulls betting on a transformative oncology platform while bears argue the stock is significantly overvalued ahead of full data disclosures and potential share dilution.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gladstone Commercial's Series B Preferred Stock About To Put More Money In Your Pocket

On 8/18/26, Gladstone Commercial Corp's 7.50% Series B Cumulative Redeemable Preferred Stock (Symbol: GOODO) will trade ex-dividend, for its monthly dividend of $0.125, payable on 8/31/26. As a percentage of GOODO's recent share price of $20.80, this dividend works out to appro...

Wall Street Bulls Look Optimistic About Gladstone Commercial (GOOD): Should You Buy?

Based on the average brokerage recommendation (ABR), Gladstone Commercial (GOOD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Gladstone Commercial (GOOD) Tops Q2 FFO and Revenue Estimates

Gladstone Commercial (GOOD) delivered FFO and revenue surprises of +8.57% and +4.69%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alexander's (ALX) Beats Q2 FFO and Revenue Estimates

Alexander's (ALX) delivered FFO and revenue surprises of +0.67% and +1.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gladstone Commercial (GOOD) Stock Declines While Market Improves: Some Information for Investors

Gladstone Commercial (GOOD) reached $12.52 at the closing of the latest trading day, reflecting a -2.64% change compared to its last close.

Here is What to Know Beyond Why Gladstone Commercial Corporation (GOOD) is a Trending Stock

Gladstone Commercial (GOOD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gladstone Commercial (GOOD) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Gladstone Commercial (GOOD) stood at $12.78, denoting a -1.69% move from the preceding trading day.

Reminder - Gladstone Commercial (GOOD) Goes Ex-Dividend Soon

Looking at the universe of stocks we cover at Dividend Channel, on 7/24/26, Gladstone Commercial Corp (Symbol: GOOD) will trade ex-dividend, for its monthly dividend of $0.10, payable on 7/31/26. As a percentage of GOOD's recent stock price of $13.09, this dividend works out to...

Gladstone Commercial (GOOD) Rises Higher Than Market: Key Facts

Gladstone Commercial (GOOD) reached $12.71 at the closing of the latest trading day, reflecting a +1.11% change compared to its last close.

Gladstone Commercial Corporation (GOOD) is Attracting Investor Attention: Here is What You Should Know  

Gladstone Commercial Corp. is a real estate investment trust, which engages in the acquisition, managing and ownership of office and industrial properties. The company was founded by David John Gladstone on February 14, 2003 and is headquartered in McLean, VA.

Gladstone Commercial Corp

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$12.91
Prev Close	$12.98
Open	$13.04
Dividend Yield	11.25%
50-Day Moving Average	$12.65
Beta	0.56
Avg. Volume	421,290.07
PE Ratio	51.54

52-Week High	$13.47
52-Week Low	$10.33
Market Capitalization	$629.73M
EPS (Annual)	$0.1406
Price to Book	4.00
Revenue Per Employee	$2.15M

Feed

News

Sentiment

Earnings

Fundamentals

Info